Pfizer has initiated multiple late-stage clinical studies for PF-4404, a novel oncology candidate targeting three distinct tumor types, with the first pivotal data readouts expected in mid-2026. In parallel, the company’s newly acquired MET-097i asset is advancing through Phase 2 weight-management trials, enrolling over 1,200 patients across North America and Europe. Management projects that combined sales from these two programs could contribute more than $5 billion in annual revenue by 2030, offsetting expected patent expirations on key franchises beginning in 2027.

In December 2025, Pfizer secured a three-year exemption from proposed import duties through an agreement with the U.S. administration, committing to modest price concessions on a portfolio of 10 high-volume medicines. This arrangement preserves an estimated $1.2 billion in annual gross profit versus full-tariff scenarios and reinforces the company’s 69% gross margin among large-cap peers. Investors will monitor whether pricing adjustments remain within the recently reported 8.4% dividend yield framework and support free cash flow targets of $17 billion for fiscal 2026.

At the World Economic Forum in Davos, CEO Albert Bourla criticized vaccine skepticism as “anti-science” and identified leadership turnover at the Department of Health and Human Services as essential for advancing U.S. immunization policy. He highlighted that reduced funding for academic research over the past five years has eroded America’s position, while China now occupies approximately 80% of top-tier rankings in global health research. Bourla urged policymakers to reverse budget cuts and bolster university-industry partnerships to safeguard Pfizer’s 25% R&D spending ratio and maintain its competitive edge in novel biologics and mRNA platforms.